Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
Go back to Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.19 -0.03 (0.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.22 | 52 Week High | $9.23 | |||
| Open | $10.10 | 52 Week Low | $1.16 | |||
| Day High | $10.36 | P/E | N/A | |||
| Day Low | $9.75 | EPS | $-0.30 | |||
| Volume | 4,230,752 | |||||
